Cargando…

Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and N-Acetylcysteine against Tobramycin-Resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii

The antibacterial activity and biofilm reduction capability of liposome formulations encapsulating tobramycin (TL), and Tobramycin-N-acetylcysteine (TNL) were tested against tobramycin-resistant strains of E. coli, K. pneumoniae and A. baumannii in the presence of several resistant genes. All antiba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alarfaj, Reem E., Alkhulaifi, Manal M., Al-Fahad, Ahmed J., Aljihani, Shokran, Yassin, Alaa Eldeen B., Alghoribi, Majed F., Halwani, Majed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778299/ https://www.ncbi.nlm.nih.gov/pubmed/35057026 http://dx.doi.org/10.3390/pharmaceutics14010130

Ejemplares similares

Enhancing azithromycin antibacterial activity by encapsulation in liposomes/liposomal-N-acetylcysteine formulations against resistant clinical strains of Escherichia coli
por: Aljihani, Shokran A., et al.
Publicado: (2020)

Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections
por: Gounden, Ronald, et al.
Publicado: (2009)

Amplification of Aminoglycoside Resistance Gene aphA1 in Acinetobacter baumannii Results in Tobramycin Therapy Failure
por: McGann, Patrick, et al.
Publicado: (2014)

Mechanisms of IS26-Mediated Amplification of the aphA1 Gene Leading to Tobramycin Resistance in an Acinetobacter baumannii Isolate
por: Harmer, Christopher J., et al.
Publicado: (2022)

Acinetobacter baumannii GC2 Sublineage Carrying the aac(6′)-Im Amikacin, Netilmicin, and Tobramycin Resistance Gene Cassette
por: Harmer, Christopher J., et al.
Publicado: (2023)

Transport of Nanoparticles and Tobramycin-loaded Liposomes in Burkholderia cepacia Complex Biofilms
por: Messiaen, Anne-Sophie, et al.
Publicado: (2013)

Synergism of azlocillin, mezlocillin, piperacillin in combination with tobramycin against Klebsiella and Pseudomonas.
por: Downs, J. T., et al.
Publicado: (1986)

Cost Reduction of Inhaled Tobramycin by Use of Preservative-Free Intravenous Tobramycin Given via Inhalation
por: Gauthier, Timothy P., et al.
Publicado: (2015)

An Explorative Review on Advanced Approaches to Overcome Bacterial Resistance by Curbing Bacterial Biofilm Formation
por: Mohamad, F, et al.
Publicado: (2023)

In Vitro Synergy of Cefamandole-Tobramycin Combinations
por: Valenti, August J., et al.
Publicado: (1977)

Tobramycin Nanoantibiotics and Their Advantages: A Minireview
por: Rosalia, Mariella, et al.
Publicado: (2022)

Efficacy of inhaled tobramycin in severe nosocomial pneumonia
por: Kuzovlev, A, et al.
Publicado: (2012)

Inhaled tobramycin for the treatment of nosocomial pneumonia in sepsis
por: Kuzovlev, A, et al.
Publicado: (2014)

Impact of tobramycin on the performance of microbial fuel cell
por: Wu, Wenguo, et al.
Publicado: (2014)

Tobramycin and vestibulotoxicity: retrospective analysis of four cases
por: Vonk, S E M, et al.
Publicado: (2022)

Development of a novel tobramycin dependent riboswitch
por: Kraus, Leon, et al.
Publicado: (2023)

Assessing tobramycin levels and renal function following the implantation of CaSO(4) beads impregnated with tobramycin: A prospective cohort study
por: Alowais, Shuroug A., et al.
Publicado: (2022)

The ineffectiveness of tobramycin combination therapy in Streptococcus faecium endocarditis.
por: Goldstein, J. A., et al.
Publicado: (1983)

Adherence with tobramycin inhaled solution and health care utilization
por: Briesacher, Becky A, et al.
Publicado: (2011)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model
por: Cao, Bao, et al.
Publicado: (2016)

Early preventive administration of inhaled tobramycin in severe polytrauma
por: Kuzovlev, A, et al.
Publicado: (2015)

Differential Effects of Linkers on the Activity of Amphiphilic Tobramycin Antifungals
por: Fosso, Marina Y., et al.
Publicado: (2018)

Parallel Evolution of Tobramycin Resistance across Species and Environments
por: Scribner, Michelle R., et al.
Publicado: (2020)

Effect of Local Delivery of Vancomycin and Tobramycin on Bone Regeneration
por: Han, Wei, et al.
Publicado: (2021)

Engineering of Streptoalloteichus tenebrarius 2444 for Sustainable Production of Tobramycin
por: Mitousis, Lena, et al.
Publicado: (2021)

Experience With Pre-Dialysis Administration of Tobramycin in the Outpatient Setting
por: Tessier, Jean-François, et al.
Publicado: (2022)

Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against Pseudomonas aeruginosa
por: Alzahrani, Nouf M., et al.
Publicado: (2022)

Green Nail Syndrome Treated with the Application of Tobramycin Eye Drop
por: Bae, Youin, et al.
Publicado: (2014)

Pharmacokinetic analysis of topical tobramycin in equine tears by automated immunoassay
por: Czerwinski, Sarah L, et al.
Publicado: (2012)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis
por: Vázquez-Espinosa, Emma, et al.
Publicado: (2015)

Free and Nanoencapsulated Tobramycin: Effects on Planktonic and Biofilm Forms of Pseudomonas
por: Sans-Serramitjana, Eulalia, et al.
Publicado: (2017)

RpoN Promotes Pseudomonas aeruginosa Survival in the Presence of Tobramycin
por: Viducic, Darija, et al.
Publicado: (2017)

Development of Tinnitus and Hyperacusis in a Mouse Model of Tobramycin Cochleotoxicity
por: Longenecker, Ryan J., et al.
Publicado: (2021)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review
por: VanDevanter, Donald R, et al.
Publicado: (2011)

Tobramycin exposure from active calcium sulfate bone graft substitute
por: Livio, Françoise, et al.
Publicado: (2014)

Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance
por: Beaudoin, T., et al.
Publicado: (2017)

RadD Contributes to R-Loop Avoidance in Sub-MIC Tobramycin
por: Negro, Veronica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7rpume8vt95okpc5n5bm8rhi6q